Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 4Prostatic Neoplasms 2Venous Thromboembolism 1Thrombocythemia, Essential 1Smoking Cessation 1Primary Myelofibrosis 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasms 1Motor Activity 1Lung Neoplasms 1Liver Cirrhosis 1Leukemia, Hairy Cell 1Inflammation 1Hemorrhage 1Fibrosis 1Fallopian Tube Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Carcinoma 1Breast Neoplasms 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 51Carboplatin 49pembrolizumab 45Magnetic Resonance Spectroscopy 43Pemetrexed 39Cisplatin 34Paclitaxel 24durvalumab 23osimertinib 20Nivolumab 19Gemcitabine 19Radiosurgery 17Docetaxel 17atezolizumab 14Taxes 12Radiotherapy 12Immunoglobulin G 12Disulfides 12130-nm albumin-bound paclitaxel 12Etoposide 11Educational Status 11Biopsy 11Radiation 10Drug Therapy 10Blood Specimen Collection 10Platinum 9Early Intervention, Educational 9Cetuximab 9Methods 8Bevacizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Aspirin × 90 days × Clear all
NCT03654105 2026-03-27

SMILE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Active not recruiting
2,000 enrolled
Thoracic

Inflammation, Lung Neoplasms, Motor Activity, Smoking Cessation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡